Syros Pharmaceuticals price target lowered to $13 from $15 at Oppenheimer

Oppenheimer lowered the firm’s price target on Syros Pharmaceuticals to $13 from $15 and keeps an Outperform rating on the shares post the Q4 results. The analyst expects 2023 will be a year of clinical execution.